TY - JOUR
T1 - Toxoplasma gondii infection and chronic schizophrenia
T2 - Is there any association?
AU - De Campos-Carli, Salvina Maria
AU - Vieira, Érica Leandro Marciano
AU - Rocha, Natalia Pessoa
AU - De Oliveira, Keliane
AU - Guimarães, Fernanda Carneiro
AU - Barbosa, Izabela Guimarães
AU - De Barros, João Luís Vieira Monteiro
AU - Okusaga, Olaoluwa
AU - Martins-Filho, Olindo Assis
AU - Salgado, João Vinícius
AU - Teixeira, Antônio Lúcio
N1 - Publisher Copyright:
© 2017, Universidade de Sao Paulo. All rights reserved.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Background: Toxoplasma gondii (T. gondii) infection has been identified as a risk factor for schizophrenia. Objectives: Herein, we sought to evaluate the association between T. gondii infection and clinical symptoms and quality of life in patients with schizophrenia. Methods: We conducted a cross-sectional study with 48 patients with chronic schizophrenia and 40 controls. Peripheral blood was drawn, and IgM and IgG anti-T. gondii antibodies were evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Depressive, positive and negative symptoms were assessed, respectively, by the Calgary Depression Scale (CDS) and the Positive and Negative Syndrome Scale (PANSS). Cognitive performance was assessed in patients by the Brazilian version of the Schizophrenia Cognition Rating Scale (SCoRS-BR). Quality of life was assessed by the Brazilian version of the Quality of Life in Schizophrenia scale (QLS-BR). Results: The prevalence and titers of T. gondii IgM and IgG antibodies did not differ between patients and controls. The positive serology for T. gondii IgG antibodies was not associated with illness symptoms, cognitive performance, depressive symptoms or quality of life. Discussion: Our findings suggest that toxoplasmosis infection is not associated with severity of symptoms, quality of life, cognitive or depressive symptoms in schizophrenia patients.
AB - Background: Toxoplasma gondii (T. gondii) infection has been identified as a risk factor for schizophrenia. Objectives: Herein, we sought to evaluate the association between T. gondii infection and clinical symptoms and quality of life in patients with schizophrenia. Methods: We conducted a cross-sectional study with 48 patients with chronic schizophrenia and 40 controls. Peripheral blood was drawn, and IgM and IgG anti-T. gondii antibodies were evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Depressive, positive and negative symptoms were assessed, respectively, by the Calgary Depression Scale (CDS) and the Positive and Negative Syndrome Scale (PANSS). Cognitive performance was assessed in patients by the Brazilian version of the Schizophrenia Cognition Rating Scale (SCoRS-BR). Quality of life was assessed by the Brazilian version of the Quality of Life in Schizophrenia scale (QLS-BR). Results: The prevalence and titers of T. gondii IgM and IgG antibodies did not differ between patients and controls. The positive serology for T. gondii IgG antibodies was not associated with illness symptoms, cognitive performance, depressive symptoms or quality of life. Discussion: Our findings suggest that toxoplasmosis infection is not associated with severity of symptoms, quality of life, cognitive or depressive symptoms in schizophrenia patients.
KW - Cognition
KW - Depression
KW - Quality of life
KW - Schizophrenia
KW - Toxoplasma gondii
UR - http://www.scopus.com/inward/record.url?scp=85042633333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042633333&partnerID=8YFLogxK
U2 - 10.1590/0101-60830000000140
DO - 10.1590/0101-60830000000140
M3 - Article
AN - SCOPUS:85042633333
SN - 0101-6083
VL - 44
SP - 145
EP - 148
JO - Revista de Psiquiatria Clinica
JF - Revista de Psiquiatria Clinica
IS - 6
ER -